breast cancer; pyrotinib; trastuzumab; pertuzumab
Showing 26 - 50 of >10,000
Breast Cancer Trial in Shanghai (Pertuzumab)
Not yet recruiting
- Breast Cancer
-
Shanghai, Shanghai, ChinaShanghai Jiaotong University School of Medicine affiliated Ruiji
Jun 4, 2023
HER2-positive Breast Cancer Trial in Guanzhou (Eribulin mesylate injection?Pertuzumab?Trastuzumab)
Recruiting
- HER2-positive Breast Cancer
- Eribulin mesylate injectionăPertuzumabăTrastuzumab
-
Guanzhou, Guangdong, ChinaLI YuDong
Jul 13, 2023
Malignant Solid Tumor Trial in Philadelphia (Biopsy, Biospecimen Collection, Echocardiography)
Active, not recruiting
- Malignant Solid Neoplasm
- Biopsy
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Nov 15, 2023
Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)
Recruiting
- Breast Cancer
- Pegylated liposomal doxorubicin
- +5 more
-
Shanghai, ChinaShanghai Pudong Hospital
Dec 11, 2022
Breast Cancer Trial in Shanghai (Dalpiciclib, Fulvestrant, Pertuzumab)
Active, not recruiting
- Breast Cancer
- Dalpiciclib
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Oct 10, 2022
Breast Tumor Female Trial (Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy)
Not yet recruiting
- Breast Neoplasm Female
- Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy
- (no location specified)
Oct 17, 2022
Metastatic Breast Cancer Trial (BDC-1001, Pertuzumab)
Not yet recruiting
- Metastatic Breast Cancer
- (no location specified)
Jul 12, 2023
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line
Recruiting
- Breast Neoplasms
- Inetetamab
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial People's Hospital
Mar 16, 2023
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease Trial in Tampa, Evanston (Radiation Therapy,
Recruiting
- HER2-positive Breast Cancer
- +2 more
- Radiation Therapy
- +2 more
-
Tampa, Florida
- +1 more
Dec 30, 2022
Locally Advanced Breast Cancer Trial in Shanghai (pyrotinib)
Recruiting
- Locally Advanced Breast Cancer
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 11, 2022
Breast Cancer Trial in Nanjing (Pyrotinib, trastuzumab, abraxane)
Not yet recruiting
- Breast Cancer
- Pyrotinib, trastuzumab, abraxane
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Dec 20, 2022
Breast Cancer Trial in Shenyang (Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole)
Recruiting
- Breast Cancer
- Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole
-
Shenyang, Liaoning, ChinaShengjing Hospital of China Medical University
Sep 12, 2022
Breast Tumors, Malignant Tumor of the Breast Trial in Multiple Locations (Trastuzumab, Pertuzumab, Vinorelbine, Paclitaxel,
Terminated
- Breast Neoplasms
- Malignant Tumor of the Breast
- Trastuzumab
- +2 more
-
Multiple Locations, Texas19 Sites
Nov 29, 2022
HER2-positive Breast Cancer, Metastatic Breast Cancer Trial in Shanghai (Trastuzumab plus chemo, Trastuzumab in combination with
Recruiting
- HER2-positive Breast Cancer
- Metastatic Breast Cancer
- Trastuzumab plus chemotherapy
- Trastuzumab in combination with pyrotinib plus chemotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 20, 2022
HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy Trial (Trastuzumab Emtansine for Injection, Pyrotinib Maleate
Not yet recruiting
- HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
- Trastuzumab Emtansine for Injection
- Pyrotinib Maleate Tablets
- (no location specified)
Sep 30, 2022
Breast Cancer Trial in Houston (Durvalumab, Trastuzumab, Pertuzumab)
Recruiting
- Breast Cancer
- Durvalumab
- +2 more
-
Houston, TexasHouston Methodist Cancer Center
Aug 5, 2022
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer Trial (KN026, HB1801, Pertuzumab)
Not yet recruiting
- First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
- KN026
- +4 more
- (no location specified)
Apr 20, 2023
Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer Trial in Shanghai (Palbociclib, trastuzumab, pyrotinib)
Recruiting
- Estrogen Receptor-positive Breast Cancer
- HER2-positive Breast Cancer
- Palbociclib
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Hospital
Sep 29, 2021
HER2-positive Early Breast Cancer Trial in China (drug, procedure, radiation)
Active, not recruiting
- HER2-positive Early Breast Cancer
- Pertuzumab IV
- +8 more
-
Beijing, China
- +17 more
Nov 21, 2022
HER2-positive Breast Cancer Trial in Tampa (biological, drug, procedure)
Recruiting
- HER2-positive Breast Cancer
- HER-2 pulsed DC1
- +4 more
-
Tampa, FloridaMoffitt Cancer Center
Oct 6, 2022
Breast Cancer Trial in Boston, Ann Arbor (drug, procedure, radiation)
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane Trial in
Recruiting
- HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
- SHR-A1811
- Pyrotinib in combination with Capecitabine.
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Aug 8, 2022
Breast Cancer Trial in Nanjing (Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate)
Recruiting
- Breast Cancer
- Inetetamab
- +2 more
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Apr 10, 2023